Professor | Xiaodong Guan | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xiaodong Guan
Contact Information	guanxiaodong@pku.edu.cn
Language ability	Chinese, English
Province	Beijing

Upload Avatar (500 x 500)

Name

Xiaodong Guan

Contact Information

guanxiaodong@pku.edu.cn

Language ability

Chinese, English

Province

Beijing

University/Lab Affiliation and Title	Peking University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2011 Ph.D. in Science: Peking University 2008 M.Sc. in Science: Peking University 2004 B.Sc. in Science: Peking University
Work Experience	2017-present - Peking University School of Pharmaceutical Sciences - Secretary of the Student Party General Branch (2017-18), Member of the Party Committee (2022), Assistant Dean (2023) 2011-present - Peking University School of Pharmaceutical Sciences, Department of Pharmaceutical Management and Clinical Pharmacy - Lecturer (2011), Associate Professor (2018), Master's Supervisor (2018), Deputy Director (2018), Director (2019), PI (2020), Doctoral Supervisor (2020), Researcher (2023) 2018.9-2019.9 - Harvard Medical School - Visiting Scholar 2004.8-2005.7 - Datong County National Complete Middle School, Xining City, Qinghai Province - Volunteer Teacher
Awards	Peking University Curriculum Ideological and Political Demonstration Course (2022) Peking University Teaching Achievement Award Second Prize (2022) Beijing Science and Technology Progress Award Second Prize (2021) Peking University School of Pharmaceutical Sciences Fourth 'My Favorite Mentor' Title (2020) 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Spotlight Poster (2020) International Society for Pharmacoepidemiology Annual Meeting John Snow Award (2018) Peking University Health Science Center Teaching Excellence Award (2017, 2018) Peking University Youth Post Expert (2017) Peking University Outstanding Communist Party Member, Peking University Outstanding Class Teacher Model (2016) Peking University Health Science Center Outstanding Teacher (2013, 2015)

University/Lab Affiliation and Title

Peking University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2011 Ph.D. in Science: Peking University
2008 M.Sc. in Science: Peking University
2004 B.Sc. in Science: Peking University

Work Experience

2017-present - Peking University School of Pharmaceutical Sciences - Secretary of the Student Party General Branch (2017-18), Member of the Party Committee (2022), Assistant Dean (2023)
2011-present - Peking University School of Pharmaceutical Sciences, Department of Pharmaceutical Management and Clinical Pharmacy - Lecturer (2011), Associate Professor (2018), Master's Supervisor (2018), Deputy Director (2018), Director (2019), PI (2020), Doctoral Supervisor (2020), Researcher (2023)
2018.9-2019.9 - Harvard Medical School - Visiting Scholar
2004.8-2005.7 - Datong County National Complete Middle School, Xining City, Qinghai Province - Volunteer Teacher

Awards

Peking University Curriculum Ideological and Political Demonstration Course (2022)
Peking University Teaching Achievement Award Second Prize (2022)
Beijing Science and Technology Progress Award Second Prize (2021)
Peking University School of Pharmaceutical Sciences Fourth 'My Favorite Mentor' Title (2020)
37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Spotlight Poster (2020)
International Society for Pharmacoepidemiology Annual Meeting John Snow Award (2018)
Peking University Health Science Center Teaching Excellence Award (2017, 2018)
Peking University Youth Post Expert (2017)
Peking University Outstanding Communist Party Member, Peking University Outstanding Class Teacher Model (2016)
Peking University Health Science Center Outstanding Teacher (2013, 2015)

Areas of Focus	Equitable Access to Medicines and Rational Use
Publications	Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis., Ma Z, Li H, Zhang Y, Zhang L, Huang G, Zhang Y, Shi L, Liu W, An Z, Guan X., 2024 The changes of different restriction level adjustments on antibiotic use in China., Du K, Wushouer H, Huang T, Zhou Y, Hu L, Yang Y, Deng Y, Zheng B, Guan X, Shi L., 2023 Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study., Zhang Y, Chen D, Cheng S, Liang Z, Yang L, Li Q, Bai L, Li H, Liu W, Shi L, Guan X., 2023 Association Between β-lactam Allergy Documentation and Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China., Hu L, Fu M, Wushouer H, Ling K, Shi L, Guan X., 2023 Appropriate use of antibiotics for acute respiratory infections at primary healthcare facilities in China: a nationwide cross-sectional study from 2017 to 2019., Fu M, Gong Z, Li C, Ling K, Zhu Y, Li H, Shi L, Guan X., 2023 The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data., Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X., 2023 Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021., Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X., 2023 Inpatient antibacterial use trends and patterns, China, 2013-2021., Wushouer H, Zhou Y, Zhang W, Hu L, Du K, Yang Y, Yao G, Little P, Zheng B, Guan X, Shi L., 2023 Newly approved cancer drugs in China - innovation and clinical benefit., Zhang Y, Wagner AK, Guan X., 2023 Benzodiazepine Receptor Agonists Prescribing for Insomnia Among Adults in Primary Health Care Facilities in Beijing, China., Fu M, Zhu Y, Gong Z, Li C, Li H, Shi L, Guan X., 2023 A comparative study of antibiotic use in China under Chinese restriction list and world health Organization AWaRe classification., Wushouer H, Yang Y, Deng Y, Zheng B, Shi L, Guan X., 2022 Inappropriate antibiotic prescribing in primary healthcare facilities in China: a nationwide survey, 2017-2019., Fu M, Gong Z, Zhu Y, Li C, Zhou Y, Hu L, Li H, Wushouer H, Guan X, Shi L., 2022 Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020., Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X., 2022 Misleading Reporting in Statistically Not Significant Oncology Trials-Joining Efforts Toward Unbiased Results Interpretation., Zhang Y, Guan X., 2021 Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs., Naci H, Guan X, Woloshin S, Xu Z, Wagner AK., 2021 Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018., Fu M, Naci H, Booth C, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner A., 2021 Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending., Huang T, Wagner A, Bai L, Huang C, Guan X, Shi L., 2021 中国国家医保谈判药品药物经济学评价研究的系统评价, 贺子璇,黄先琴,陈定一,王国安,朱玥桢,韩晟,管晓东,史录文., 2023 医务人员“共诊患者”网络研究的范围综述, 杨雨,胡华杰,黄涛,巩志文,管晓东,史录文., 2023 超说明书用药医疗损害责任纠纷判决与循证证据的相关性分析, 保琦,胡琳,胡华杰,黄涛,傅孟元,海沙尔江·吾守尔,管晓东,史录文., 2022

Areas of Focus

Equitable Access to Medicines and Rational Use

Publications

Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis., Ma Z, Li H, Zhang Y, Zhang L, Huang G, Zhang Y, Shi L, Liu W, An Z, Guan X*., 2024
The changes of different restriction level adjustments on antibiotic use in China., Du K, Wushouer H, Huang T, Zhou Y, Hu L, Yang Y, Deng Y, Zheng B, Guan X*, Shi L*., 2023
Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study., Zhang Y, Chen D, Cheng S, Liang Z, Yang L, Li Q, Bai L, Li H, Liu W, Shi L, Guan X*., 2023
Association Between β-lactam Allergy Documentation and Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China., Hu L, Fu M, Wushouer H, Ling K, Shi L, Guan X*., 2023
Appropriate use of antibiotics for acute respiratory infections at primary healthcare facilities in China: a nationwide cross-sectional study from 2017 to 2019., Fu M, Gong Z, Li C, Ling K, Zhu Y, Li H, Shi L, Guan X*., 2023
The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data., Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X*., 2023
Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021., Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X*., 2023
Inpatient antibacterial use trends and patterns, China, 2013-2021., Wushouer H, Zhou Y, Zhang W, Hu L, Du K, Yang Y, Yao G, Little P, Zheng B, Guan X*, Shi L., 2023
Newly approved cancer drugs in China - innovation and clinical benefit., Zhang Y, Wagner AK, Guan X*., 2023
Benzodiazepine Receptor Agonists Prescribing for Insomnia Among Adults in Primary Health Care Facilities in Beijing, China., Fu M, Zhu Y, Gong Z, Li C, Li H, Shi L, Guan X*., 2023
A comparative study of antibiotic use in China under Chinese restriction list and world health Organization AWaRe classification., Wushouer H, Yang Y, Deng Y, Zheng B, Shi L, Guan X*., 2022
Inappropriate antibiotic prescribing in primary healthcare facilities in China: a nationwide survey, 2017-2019., Fu M, Gong Z, Zhu Y, Li C, Zhou Y, Hu L, Li H, Wushouer H, Guan X*, Shi L., 2022
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020., Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X*., 2022
Misleading Reporting in Statistically Not Significant Oncology Trials-Joining Efforts Toward Unbiased Results Interpretation., Zhang Y, Guan X., 2021
Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs., Naci H, Guan X, Woloshin S, Xu Z, Wagner AK., 2021
Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018., Fu M, Naci H, Booth C, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner A., 2021
Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending., Huang T, Wagner A, Bai L, Huang C, Guan X*, Shi L., 2021
中国国家医保谈判药品药物经济学评价研究的系统评价, 贺子璇,黄先琴,陈定一,王国安,朱玥桢,韩晟,管晓东*,史录文., 2023
医务人员“共诊患者”网络研究的范围综述, 杨雨,胡华杰,黄涛,巩志文,管晓东*,史录文., 2023
超说明书用药医疗损害责任纠纷判决与循证证据的相关性分析, 保琦,胡琳,胡华杰,黄涛,傅孟元,海沙尔江·吾守尔,管晓东*,史录文., 2022

Equitable Access Medicines Rational Use Pharmaceutical Policy Healthcare Public Health Drug Pricing Clinical Pharmacy Pharmacoeconomics Health Policy

Jing Yuan - Fudan University

Lu-Wen Shi - Peking University

Xiaohui Xie - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us